Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
PTLA's Cash to Debt is ranked higher than
76% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. PTLA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PTLA' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6679
N/A
No Debt
Equity to Asset 0.80
PTLA's Equity to Asset is ranked higher than
63% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. PTLA: 0.80 )
Ranked among companies with meaningful Equity to Asset only.
PTLA' s Equity to Asset Range Over the Past 10 Years
Min: -1.31  Med: 0.83 Max: 0.91
Current: 0.8
-1.31
0.91
F-Score: 3
Z-Score: 5.93
M-Score: 304.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1368.90
PTLA's Operating margin (%) is ranked lower than
81% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. PTLA: -1368.90 )
Ranked among companies with meaningful Operating margin (%) only.
PTLA' s Operating margin (%) Range Over the Past 10 Years
Min: -1882.15  Med: -426.26 Max: 25.46
Current: -1368.9
-1882.15
25.46
Net-margin (%) -1361.05
PTLA's Net-margin (%) is ranked lower than
81% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. PTLA: -1361.05 )
Ranked among companies with meaningful Net-margin (%) only.
PTLA' s Net-margin (%) Range Over the Past 10 Years
Min: -1876.59  Med: -424.48 Max: 25.61
Current: -1361.05
-1876.59
25.61
ROE (%) -64.09
PTLA's ROE (%) is ranked lower than
69% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. PTLA: -64.09 )
Ranked among companies with meaningful ROE (%) only.
PTLA' s ROE (%) Range Over the Past 10 Years
Min: -159.12  Med: -58.44 Max: -42.58
Current: -64.09
-159.12
-42.58
ROA (%) -53.40
PTLA's ROA (%) is ranked lower than
72% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. PTLA: -53.40 )
Ranked among companies with meaningful ROA (%) only.
PTLA' s ROA (%) Range Over the Past 10 Years
Min: -49.27  Med: -35.34 Max: 20.67
Current: -53.4
-49.27
20.67
ROC (Joel Greenblatt) (%) -4690.12
PTLA's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. PTLA: -4690.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PTLA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5117.78  Med: -3052.63 Max: 1029.06
Current: -4690.12
-5117.78
1029.06
Revenue Growth (3Y)(%) -56.20
PTLA's Revenue Growth (3Y)(%) is ranked lower than
86% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. PTLA: -56.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PTLA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: -56.2
Current: -56.2
» PTLA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

PTLA Guru Trades in Q2 2015

Ken Fisher 80,300 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 27,400 sh (-54.30%)
» More
Q3 2015

PTLA Guru Trades in Q3 2015

Paul Tudor Jones 12,214 sh (New)
Ken Fisher 80,300 sh (unchged)
Jim Simons 23,800 sh (-13.14%)
» More
Q4 2015

PTLA Guru Trades in Q4 2015

Jim Simons 139,100 sh (+484.45%)
Paul Tudor Jones 24,541 sh (+100.93%)
Ken Fisher 80,300 sh (unchged)
Samuel Isaly 475,700 sh (unchged)
» More
Q1 2016

PTLA Guru Trades in Q1 2016

Steven Cohen 431,200 sh (New)
Jim Simons 474,800 sh (+241.34%)
Paul Tudor Jones 30,442 sh (+24.05%)
Samuel Isaly 725,700 sh (+52.55%)
Ken Fisher 80,300 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PTLA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:PFSCF, NAS:MCRB, NAS:ALDR, NAS:INVA, NYSE:PBYI, OTCPK:SXMDF, NAS:FPRX, NYSE:AXON, NAS:SAGE, OTCPK:GENSF, NAS:RLYP, NYSE:EBS, NAS:XLRN, NAS:ONCE, NAS:AAAP, NAS:HALO, NAS:ARIA, NAS:ACOR, NAS:ACHN, NAS:INSY » details
Traded in other countries:0PP.Germany,
Portola Pharmaceuticals Inc is a biopharmaceutical company. It develops & commercializes novel therapeutics in the areas of thrombosis, other hematologic disorders & inflammation for patients who currently have limited or no approved treatment options.

Portola Pharmaceuticals Inc was incorporated in Delaware in September 2003. The Company is a biopharmaceutical company engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options. Its two programs address significant unmet medical needs in the areas of thrombosis or blood clots. Its compound Betrixaban is a novel oral once-daily inhibitor of Factor Xa in Phase 3 development for extended duration prophylaxis, or preventive treatment, of a form of thrombosis known as venous thromboembolism, or VTE, in acute medically ill patients. The Company's current product candidates in development includes: Betrixaban, PRT4445, PRT2070, and PRT2607. Betrixaban is a novel oral once-daily inhibitor of Factor Xa in development for extended duration VTE prophylaxis in acute medically ill patients for up to 35 days. PRT4445 is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. PRT2070 is an orally available, potent inhibitor of Syk and JAK. PRT2607 is an orally available, potent and selective inhibitor of Syk. The Company faces competition from large and small pharmaceutical and biotechnology companies, specialty pharmaceutical companies, generic drug companies, academic institutions, government agencies and research institutions and others.

Ratios

vs
industry
vs
history
P/B 3.96
PTLA's P/B is ranked lower than
54% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. PTLA: 3.96 )
Ranked among companies with meaningful P/B only.
PTLA' s P/B Range Over the Past 10 Years
Min: 3.07  Med: 4.35 Max: 9.29
Current: 3.96
3.07
9.29
P/S 78.10
PTLA's P/S is ranked lower than
80% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. PTLA: 78.10 )
Ranked among companies with meaningful P/S only.
PTLA' s P/S Range Over the Past 10 Years
Min: 6.67  Med: 94.59 Max: 277.56
Current: 78.1
6.67
277.56
EV-to-EBIT -4.23
PTLA's EV-to-EBIT is ranked lower than
99.99% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. PTLA: -4.23 )
Ranked among companies with meaningful EV-to-EBIT only.
PTLA' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.2  Med: -7.35 Max: -1.3
Current: -4.23
-13.2
-1.3
EV-to-EBITDA -4.25
PTLA's EV-to-EBITDA is ranked lower than
99.99% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. PTLA: -4.25 )
Ranked among companies with meaningful EV-to-EBITDA only.
PTLA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.3  Med: -7.45 Max: -1.3
Current: -4.25
-13.3
-1.3
Current Ratio 8.32
PTLA's Current Ratio is ranked higher than
70% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. PTLA: 8.32 )
Ranked among companies with meaningful Current Ratio only.
PTLA' s Current Ratio Range Over the Past 10 Years
Min: 5.12  Med: 7.67 Max: 10.67
Current: 8.32
5.12
10.67
Quick Ratio 8.32
PTLA's Quick Ratio is ranked higher than
72% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. PTLA: 8.32 )
Ranked among companies with meaningful Quick Ratio only.
PTLA' s Quick Ratio Range Over the Past 10 Years
Min: 5.12  Med: 7.67 Max: 10.67
Current: 8.32
5.12
10.67
Days Sales Outstanding 152.35
PTLA's Days Sales Outstanding is ranked lower than
85% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. PTLA: 152.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
PTLA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.16  Med: 4.47 Max: 30.24
Current: 152.35
2.16
30.24

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.47
PTLA's Price/Net Cash is ranked higher than
58% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. PTLA: 4.47 )
Ranked among companies with meaningful Price/Net Cash only.
PTLA' s Price/Net Cash Range Over the Past 10 Years
Min: 3.52  Med: 6.25 Max: 7.91
Current: 4.47
3.52
7.91
Price/Net Current Asset Value 4.19
PTLA's Price/Net Current Asset Value is ranked higher than
58% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. PTLA: 4.19 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PTLA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.3  Med: 6.06 Max: 7.43
Current: 4.19
3.3
7.43
Price/Tangible Book 3.98
PTLA's Price/Tangible Book is ranked higher than
52% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. PTLA: 3.98 )
Ranked among companies with meaningful Price/Tangible Book only.
PTLA' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.14  Med: 4.74 Max: 6.96
Current: 3.98
3.14
6.96
Price/Median PS Value 0.83
PTLA's Price/Median PS Value is ranked higher than
67% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. PTLA: 0.83 )
Ranked among companies with meaningful Price/Median PS Value only.
PTLA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.08  Med: 1.03 Max: 2.28
Current: 0.83
0.08
2.28
Earnings Yield (Greenblatt) (%) -23.45
PTLA's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. PTLA: -23.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PTLA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -36.03  Med: 0.00 Max: 0
Current: -23.45
-36.03
0

More Statistics

Revenue (TTM) (Mil) $17.97
EPS (TTM) $ -4.55
Beta1.20
Short Percentage of Float7.06%
52-Week Range $18.20 - 57.96
Shares Outstanding (Mil)56.47

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16
Revenue (Mil $)
EPS ($) -3.80
EPS w/o NRI ($) -3.80
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for PTLA

Headlines

Articles On GuruFocus.com
Paulson Bets Again On Mallinckrodt Aug 07 2014 

More From Other Websites
Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PTLA-US :... Jul 27 2016
Two Under The Radar Biotech Decisions To Watch Next Month Jul 25 2016
Six Major Biotech Acquisitions You Could See in 2016 (Part 2) Jul 22 2016
PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 22 2016
ETF’s with exposure to Portola Pharmaceuticals, Inc. : June 20, 2016 Jun 20 2016
Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PTLA-US :... Jun 17 2016
Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for... Jun 01 2016
Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for... Jun 01 2016
Portola Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference May 31 2016
Portola Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference May 31 2016
Portola Pharma downgraded by Credit Suisse May 31 2016
Portola Pharmaceuticals Reveals Full Results Of Final Stage APEX Trial Of Betrixaban May 27 2016
Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at... May 27 2016
Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at... May 27 2016
Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa™... May 23 2016
Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa™... May 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)